Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.
The development process will follow the international guidelines published by the EORTC
Quality of Life Group (QLG). This process will follow three main phases.
Phase 1 of will deal with the review of the literature, identification of an item list and
interviews with experts in the treatment of CML and CML patients (undergoing all possible
In Phase II the identified issues from Phase I will be worded and translated into possible
items for the provisional questionnaire using existing EORTC questionnaires and the EORTC
QLG Item Bank.
In the Phase III the provisional CML questionnaire will be pre-tested by to a larger sample
of CML patients (not the same patients involved in previous phases) and individual
structured interviews will be conducted as well. These latter will identify questions that
might be irrelevant or whether there will be additional issues not previously included.
Overall up to 480 patients will be enrolled in this study (up to 180 in phase I and up to
300 in phase III).
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Development of an EORTC questionnaire to assess HRQOL of patients with CML.
Fabio Efficace, PhD
GIMEMA DATA CENTER, ROME, ITALY
Italy: Ethics Committee
QoL - CML0310
|Dana-Farber Cancer Institute Harvard University||Boston, Massachusetts|